Sugi Predict

Sugi Predict / Compounds / SCHEMBL286232

SCHEMBL286232

SCHEMBL286232

CCOC(=O)c1ccc(C#N)cc1C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 2/20 0.49
▸ CA1 P00915 2/20 0.49
▸ CA2 P00918 2/20 0.49
▸ CA7 P43166 2/20 0.49
▸ CA9 Q16790 2/20 0.49
▸ CA14 Q9ULX7 2/20 0.49
▸ TSHR P16473 2/20 0.49
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ NPSR1 Q6W5P4 1/20 0.48
▸ KDM4E B2RXH2 6/20 0.48
▸ GLA P06280 1/20 0.48
▸ ATM Q13315 1/20 0.48
▸ ALDH1A1 P00352 4/20 0.47
▸ MAPT P10636 3/20 0.47
▸ HSD17B10 Q99714 2/20 0.47
▸ GAA P10253 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ TP53 P04637 1/20 0.47
▸ ALOX15 P16050 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6883767 0.89 TSHR (0.55) CA12CA1CA2CA7CA9
SCHEMBL4178450 0.86 CA12 (0.47) CA12CA1CA2CA7CA9
SCHEMBL30294289 0.84 TSHR (0.46) CA12CA1CA2CA7CA9
SCHEMBL7992182 0.84 CYP4F2 (0.48) CA12CA1CA2CA7CA9
SCHEMBL22852764 0.84 TSHR (0.46) CA12CA1CA2CA7CA9
SCHEMBL10411943 0.84 CA12 (0.49) CA12CA1CA2CA7CA9
SCHEMBL289565 0.83 LRRK2 (0.45) CA12CA1CA2CA7CA9
SCHEMBL7986113 0.83 PDE5A (0.48) CA12CA1CA2CA7CA9
SCHEMBL13563786 0.83 KDM4E (0.47) CA12CA1CA2CA7CA9
SCHEMBL25758221 0.83 ADRB2 (0.40) TSHRSMN1; SMN2MAPK1NPSR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240383908-A1 SYNTHESIS AND APPLICATION OF PHOSPHATASE DEGRADER HINOVA PHARMACEUTICALS INC. (CN) 2024-11-21 — — US disclosed
CN-115594666-B Synthesis and application of phosphatase degradation agent 海创药业股份有限公司 2024-05-31 — — CN disclosed
EP-4368614-A1 SYNTHESIS AND APPLICATION OF PHOSPHATASE DEGRADER Hinova Pharmaceuticals Inc. (CN) 2024-05-15 — — EP disclosed
CN-115594666-A Synthesis and application of phosphatase degrading agent 海创药业股份有限公司（CN） 2023-01-13 — — CN disclosed
WO-2023280237-A1 SYNTHESIS AND APPLICATION OF PHOSPHATASE DEGRADER 海创药业股份有限公司 2023-01-12 — — WO disclosed
WO-2023280237-A1 SYNTHESIS AND APPLICATION OF PHOSPHATASE DEGRADER 海创药业股份有限公司 2023-01-12 — — WO disclosed
CN-106242998-B Use of 4-cyano-3-benzoylamino-N-phenyl-benzamides in pesticides 先正达参股股份有限公司 2021-11-05 — — CN disclosed
EP-3020716-A1 PHENOXYMETHYL HETEROCYCLIC COMPOUNDS Forum Pharmaceuticals Inc. (US) 2016-05-18 — — EP disclosed
CN-105125547-A FORUM PHARMACEUTICALS INC FORUM PHARMACEUTICALS INC 2015-12-09 — — CN disclosed
US-20150322069-A1 PHENOXYMETHYL HETEROCYCLIC COMPOUNDS FMR LLC 2015-11-12 — — US disclosed
US-20070021489-A1 Fibrinogen receptor antagonists and their use NICHOLAS PIRAMAL INDIA LIMITED (IN) 2007-01-25 — — US disclosed
US-20070015802-A1 chromenone derivatives of nitrogen-, oxygen- or sulfur-containing saturated heterocycles; preparation by cyclizing benzoyl intermediates; antiproliferative agents; 2-(2-Chloro-phenyl)-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl)-5,7-dimethoxy-chromen-4-one; acidification NICHOLAS PIRAMAL INDIA LIMITED (IN) 2007-01-18 — — US disclosed
EP-1677783-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE Nicholas Piramal India Limited (IN) 2006-07-12 — — EP disclosed
CN-1668613-A Flavone derivatives as cyclin dependent kinase inhibitors NICHOLAS PIRAMAL INDIA LTD (IN) 2005-09-14 — — CN disclosed
EP-1556375-A2 FLAVONE DERIVATIVES AS INHIBITORS OF CYCLIN-DEPENDENT KINASES Nicholas Piramal India Limited (IN) 2005-07-27 — — EP disclosed
WO-2005035495-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE NICHOLAS PIRAMAL INDIA LIMITED (IN) 2005-04-21 — — WO disclosed
US-20040106581-A1 Inhibitors of cyclin-dependent kinases and their use NICHOLAS PIRAMAL INDIA LIMITED (IN) 2004-06-03 — — US disclosed
WO-2004004632-A2 FLAVONE DERIVATIVES AS INHIBITORS OF CYCLIN-DEPENDENT KINASES NICHOLAS PIRAMAL INDIA LIMITED (IN) 2004-01-15 — — WO disclosed
US-6265418-B1 ANTICOAGULANTS UBE INDUSTRIES, LTD. (JP) 2001-07-24 — — US disclosed
EP-1020467-A1 N-ACYLAMINO ACID AMIDE COMPOUNDS AND INTERMEDIATES FOR PREPARATION THEREOF UBE INDUSTRIES LIMITED (JP) 2000-07-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106581-A1 Inhibitors of cyclin-dependent kinases and their use CCNK, CCNI, CDK1 CA12 3627/4885CA1 2593/4885CA2 1872/4885
US-20150322069-A1 PHENOXYMETHYL HETEROCYCLIC COMPOUNDS PDE3A, PDE2A, PDE5A CA12 2975/4885CA1 1632/4885CA2 647/4885
US-20070021489-A1 Fibrinogen receptor antagonists and their use FGB, F13B, F2 CA12 4274/4885CA1 4797/4885CA2 4212/4885
US-20240383908-A1 SYNTHESIS AND APPLICATION OF PHOSPHATASE DEGRADER DUSP1, PPM1D, PTPN1 CA12 361/4885CA1 281/4885CA2 586/4885
US-20070015802-A1 chromenone derivatives of nitrogen-, oxygen- or sulfur-containing saturated heterocycles; preparation by cyclizing benzoyl intermediates; antiproliferative agents; 2-(2-Chloro-phenyl)-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl)-5,7-dimethoxy-chromen-4-one; acidification CCNI, CDK1, CCNA1 CA12 1564/4885CA1 991/4885CA2 339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.